journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/28125950/fall-related-healthcare-use-and-costs-in-neurogenic-orthostatic-hypotension-with-parkinson-s-disease
#1
Clement François, Italo Biaggioni, Cyndya Shibao, Augustina Ogbonnaya, Huai-Che Shih, Eileen Farrelly, Adam Ziemann, Amy Duhig
AIMS: To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH). MATERIALS AND METHODS: MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-December 31, 2013) were used to identify PD and probable PD + nOH patients. The first medical or prescription claim suggesting these diagnoses served as the index date...
February 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28092219/the-21st-century-cures-act-pharmacoeconomic-boon-or-bane
#2
Roger Lee Mendoza
Barriers to entry in healthcare markets constitute one of the overriding concerns of health economists. The recent enactment of the 21st Century Cures Act in the United States reduces statutory entry barriers to the discovery, development, testing, and licensing of drugs and medical devices. Drug and device makers also see the burdensome and time-consuming requirements of the Food and Drug Administration?s approval process as key barriers to lowering the costs of their products, considering it takes a decade of research amounting to $1 billion just to bring a single drug to the market...
February 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28151036/the-cost-of-warfarin-treatment-for-stroke-prevention-in-patients-with-nonvalvular-atrial-fibrillation-in-russia-from-a-collective-perspective
#3
J B Briere, K Bowrin, R Wood, J Roberts, B Tatarsky
AIMS: Vitamin K antagonists (VKAs) are used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) but necessitate regular monitoring of prothrombin time via international normalized ratio (INR) testing. This study explores the economic burden of VKA therapy for Russian patients with NVAF. METHOD: Cardiologists provided clinical characteristics and healthcare resource use data relating to the patient's first year of treatment. Data were used to quantify direct medical costs (INR testing, consultations, drug costs)...
February 2, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28145783/the-budget-impact-of-using-enteric-coated-aspirin-325mg-immediate-release-omeprazole-40mg-to-prevent-recurrent-cardiovascular-events
#4
Wenjie Zhang, Yi Han, John G Fort, David Schofield, James P Tursi
OBJECTIVE: Aspirin (acetylsalicylic acid; ASA) is commonly used for secondary prevention of cardiovascular (CV) events but may be associated with gastrointestinal (GI) adverse events, which can reduce adherence. Use of ASA co-therapy with proton pump inhibitors in patients at risk may be suboptimal. PA32540 (Yosprala(TM)) is a coordinated-delivery tablet combining EC-ASA 325 mg and immediate-release omeprazole 40 mg. The objective of this flexible budget impact model was to project the financial consequences of introducing PA32540 325 mg/40 mg to prevent recurrent CV events while reducing ASA-associated GI events in US adults...
February 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28133990/economic-outcomes-with-the-conversion-of-insulin-delivery-methods-in-hospitals
#5
Kari A Kelton, Sinem Perk, Scott Loveland, Magaly Perez-Nieves, Haoda Fu, Xiaomei Peng
PURPOSE: Evaluate the insulin wastage and associated acquisition costs when switching from individual patient supply (IPS) of 3-mL pens of rapid-acting insulin (RAI) aspart to floor stock (FS) dispensing of 3-mL vials of RAI lispro and with conversion from IPS of 3-mL pens to centralized unit dose (CUD) of 10-mL vials of basal insulin detemir. METHODS: Data from September 2010 to December 2012 from 3 hospitals in the Roper St. Francis Healthcare (RSFH) were used: Roper Hospital (368 beds), Bon Secours St...
January 30, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28128669/economic-burden-of-comorbid-chronic-kidney-disease-and-diabetes
#6
R Brett McQueen, Sepehr Farahbakhshian, Kelly F Bell, Kavita V Nair, Joseph J Saseen
OBJECTIVE: Estimate real-world healthcare utilization and expenditures across the spectrum of chronic kidney disease (CKD) as determined by estimated glomerular filtration rate (eGFR) categories in patients with diabetes. METHODS: We employed a retrospective cohort study design using the Truven Healthcare and Claims Dataset from 2009 to 2012. Index date was defined as the first eGFR value during a continuous enrollment period of 24 months. Cohorts of patients were stratified by Kidney Disease: Improving Global Outcomes CKD stage based on eGFR (stages 1: ≥90 mL/min/1...
January 27, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28125918/assessment-of-the-quality-of-pharmacoeconomic-evaluation-literature-in-china
#7
Fang Zhang, Xu He, Wei Xiang, Shu Chuen Li
OBJECTIVE: To evaluate the quality of Chinese pharmacoeconomic-evaluation literature published between 2012-2014 retrieved from the Chinese National Knowledge Infrastructure (CNKI) in order to assess their adherence to recommendations of the Chinese Pharmacoeconomic Guidelines. METHODS: Identified literature was screened according to pre-specified criteria to access legibility for inclusion. Each included piece of literature was systematically compared against the recommendations proposed by the relevant Chinese guidelines...
January 27, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28097904/estimated-burden-of-cardiovascular-disease-and-value-based-price-range-for-evolocumab-in-a-high-risk-secondary-prevention-population-in-the-us-payer-context
#8
Peter P Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira, Jeroen P Jansen
AIM: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. MATERIALS AND METHODS: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into four cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (n = 1448), acute coronary syndrome (ACS) (n = 602), ischemic stroke (IS) (n = 151), and heart failure (HF) (n = 291) incident cohorts...
January 25, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28112566/costs-of-providing-infusion-therapy-for-patients-with-inflammatory-bowel-disease-in-a-hospital-based-infusion-center-setting
#9
Anita Afzali, Kristine Ogden, Michael L Friedman, Jingdong Chao, Anthony Wang
Aims Inflammatory bowel disease (IBD) (e.g., ulcerative colitis [UC] and Crohn's disease [CD]) severely impacts patient quality of life. Moderate to severe disease is often treated with biologics requiring infusion therapy, adding incremental costs beyond drug costs. This study evaluates US hospital-based infusion services costs for treatment of UC or CD patients receiving infliximab or vedolizumab therapy. Materials and methods A model was developed, estimating annual costs of providing monitored infusions using activity-based costing framework approach...
January 23, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28107090/cost-effectiveness-analysis-in-the-spanish-setting-of-the-peak-trial-of-panitumumab-plus-mfolfox6-compared-with-bevacizumab-plus-mfolfox6-for-first-line-treatment-of-patients-with-wild-type-ras-metastatic-colorectal-cancer
#10
Fernando Rivera, Manuel Valladares, Salvador Gea, Noemí López-Martínez
OBJECTIVE: To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) versus bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain. METHODS: A semi-Markov model was developed including the following health states: Progression free; Progressive disease: Treat with best supportive care; Progressive disease: Treat with subsequent active therapy; Attempted resection of metastases; Disease free after metastases resection; Progressive disease: after resection and relapse; Death...
January 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28105869/cost-effectiveness-and-sustainability-of-breast-cancer-screening-and-new-anticancer-drugs
#11
Giorgio Mustacchi, Daniele Generali
No abstract text is available yet for this article.
January 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28097913/cost-consequence-analysis-of-different-active-flowable-hemostatic-matrices-in-cardiac-surgical-procedures
#12
D Makhija, M Rock, Y Xiong, J D Epstein, M R Arnold, O M Lattouf, D Calcaterra
BACKGROUND: A recent retrospective comparative effectiveness study found that use of FLOSEAL® Hemostatic Matrix in cardiac surgery was associated with significantly lower risks of complications, blood transfusions, surgical revisions and shorter length of surgery than use of SURGIFLO(®) Hemostatic Matrix. These outcome improvements in cardiac surgery procedures may translate to economic savings for hospitals and payers. OBJECTIVE: The objective of this study was to estimate the cost-consequence of two flowable hemostatic matrices (FLOSEAL or SURGIFLO) in cardiac surgeries for US hospitals...
January 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28092235/hospital-cost-and-length-of-stay-in-idiopathic-pulmonary-fibrosis
#13
Joshua J Mooney, Karina Raimundo, Eunice Chang, Michael S Broder
OBJECTIVE: To provide a detailed picture of the economic impact of hospitalization in idiopathic pulmonary fibrosis (IPF) and to identify factors associated with cost and length of stay (LOS). METHODS: In this retrospective cross-sectional study using the Nationwide Inpatient Sample (NIS), we included hospitalizations for IPF (ICD-9-CM 516.3) with a principal diagnosis of respiratory disease (ICD-9-CM 460-519) from 2009-2011; lung transplant admissions were excluded...
January 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28058859/clinical-characteristics-treatment-patterns-and-socio-economic-burden-of-copd-in-bulgaria
#14
Maria Kamusheva, Maria Dimitrova, Job Fm van Boven, Maarten J Postma, Thys van der Molen, Janwillem Wh Kocks, Konstantin Mitov, Miglena Doneva, Daniela Petrova, Ognyan Georgiev, Valentina Petkova, Guenka Petrova
INTRODUCTION: While the impact of COPD in Western-Europe is known, data from Eastern-Europe is scarce. We aimed to evaluate clinical characteristics, treatment patterns and the socio-economic burden of COPD in Eastern-Europe, taking Bulgaria as a reference case. METHODS: A representative sample of Bulgarian patients with COPD was randomly chosen by pulmonologists based on the following inclusion criteria: COPD diagnosis with at least one year of living with COPD, ≥40 years of age, and use of COPD medication...
January 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28010149/outcomes-of-tumor-necrosis-factor-inhibitor-cycling-versus-switching-to-a-disease-modifying-anti-rheumatic-drug-with-a-new-mechanism-of-action-among-patients-with-rheumatoid-arthritis
#15
Benjamin Chastek, Laura K Becker, Chieh-I Chen, Puneet Mahajan, Jeffrey R Curtis
OBJECTIVES: To examine treatment patterns, treatment effectiveness, and treatment costs for 1 year after patients with rheumatoid arthritis switched from a tumor necrosis factor inhibitor (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), either cycling to another TNFi ("TNFi cyclers") or switching to a new mechanism of action (abatacept, tocilizumab, or tofacitinib) ("new MOA switchers"). METHODS: This retrospective cohort study used administrative claims data for a national insurer...
January 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28035846/employment-and-absenteeism-in-working-age-persons-with-multiple-sclerosis
#16
Amber Salter, Nina Thomas, Tuula Tyry, Gary Cutter, Ruth Ann Marrie
AIMS: To better understand the impact of the clinical course of multiple sclerosis (MS) and disability on employment, absenteeism, and related factors. MATERIALS AND METHODS: We included respondents to the North American Research Committee on Multiple Sclerosis Registry spring 2015 update survey who were United States or Canadian residents, aged 18-65 years and reported having relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS)...
December 30, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28035843/within-the-triangle-of-healthcare-legacies-comparing-the-performance-of-south-eastern-european-health-systems
#17
Mihajlo Michael Jakovljevic, Jelena Arsenijevic, Milena Pavlova, Nick Verhaeghe, Ulrich Laaser, Wim Groot
OBJECTIVE: Inter-regional comparison of health-reform outcomes in south-eastern Europe (SEE). METHODS: Macro-indicators were obtained from the WHO Health for All Database. Inter-regional comparison among post-Semashko, former Yugoslavia and prior-1989-free-market SEE economies was conducted. RESULTS: United Nations Development Program Human Development Index growth was strongest among prior-free-market SEE followed by former Yugoslavia and post-Semashko...
December 30, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28008770/the-budget-impact-and-cost-effectiveness-of-defibrotide-for-treatment-of-veno-occlusive-disease-with-multi-organ-dysfunction-in-patients-post-hematopoietic-stem-cell-transplant
#18
David L Veenstra, Gregory F Guzauskas, Kathleen F Villa, Denise M Boudreau
BACKGROUND: A Phase-3 study of defibrotide compared with historical controls demonstrated a 23% improvement in 100-day survival post-hematopoietic stem cell transplantation (HSCT) among patients with veno-occlusive disease with multi-organ dysfunction (VOD with MOD). AIM: To estimate the budget impact and cost-effectiveness of introducing defibrotide to a transplant center. METHODS: We developed a budget impact model from the perspective of a bone-marrow transplant center...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28008769/a-discrete-event-simulation-to-model-the-cost-utility-of-fingolimod-and-natalizumab-in-rapidly-evolving-severe-relapsing-remitting-multiple-sclerosis-in-the-uk
#19
Stephen Montgomery, Maciej Maruszczak, David Slater, Jeanette Kusel, Richard Nicholas, Nicholas Adlard
OBJECTIVE: Two disease modifying therapies are licensed in the EU for use in rapidly-evolving severe (RES) relapsing-remitting multiple sclerosis (RRMS), fingolimod and natalizumab. Here a discrete event simulation (DES) model to analyse the cost-effectiveness of natalizumab and fingolimod in the RES population, from the perspective of the National Health Service (NHS) in the UK, is reported. METHODS: A DES model was developed to track individual RES patients, based on Expanded Disability Status Scale scores...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28008768/the-cost-effectiveness-of-dulaglutide-versus-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-in-spain-in-patients-with-bmi%C3%A2-30%C3%A2-kg-m-2
#20
Tatiana Dilla, Dimitra Alexiou, Ismini Chatzitheofilou, Ruba Ayyub, Julia Lowin, Kirsi Norrbacka
OBJECTIVE: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 (GLP-1) receptor agonist, for the treatment of type two diabetes mellitus (T2DM). The objective was to estimate the cost-effectiveness of dulaglutide once weekly versus liraglutide 1.8mg once daily for the treatment of T2DM in Spain in patients with a BMI≥30 kg/m(2). METHODS: The IMS CORE Diabetes Model (CDM) was used to estimate costs and outcomes from the perspective of Spanish National Health System, capturing relevant direct medical costs over a lifetime time horizon...
December 23, 2016: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"